A new study highlights the Cardio-Ankle Vascular Index (CAVI) as a powerful tool for predicting COPD progression and outcomes ...

FDA approves Nucala as add-on therapy for COPD with high eosinophils, offering new hope by reducing flare-ups in patients ...

University of Alabama at Birmingham-led researchers have refined and validated a new framework for diagnosing chronic ...

The FDA granted approval to mepolizumab for treating adults with inadequately controlled COPD and an eosinophilic phenotype, ...

We have developed a new, multidimensional diagnostic schema for COPD that incorporates spirometry, symptoms, and imaging and ...

London: GSK plc has received approval from the US Food and Drug Administration (FDA) for Nucala (mepolizumab) as an add-on ...

While not the first biologic to break into the COPD sector – Sanofi and Regeneron took that crown with the approval of their ...

Management of COPD in people with learning disabilities can be made more complex due to medical compliance issues and inhaler ...

Mepolizumab has had a bumpy road to arriving at its indication in COPD. An FDA advisory committee in 2018 declined to ...

Pharma group GSK has announced that US regulators have approved for use its Nucala treatment for adults with chronic ...

A BMJ Open Respiratory Research study finds women aged over 40 face a 50% higher risk of developing COPD than men—even ...

Eucalyptus oil was first used by Aboriginal Australians, who crushed the leaves for their antiseptic properties or steamed ...